Immunization with the long-acting monoclonal antibody nirsevimab may provide stronger protection against hospitalizations for ...

(WXYZ) — In today’s Health Alert, a new study shows that one dose of the RSV vaccine may protect older adults through not just one, but two cold and flu seasons ...

Six recent studies conclude that maternal respiratory syncytial virus (RSV) vaccination and the long-acting monoclonal ...

Increased risk for hypertensive disorders was present, but modest, in a new surveillance analysis of a bivalent respiratory syncytial virus (RSV) prefusion F subunit-based (RSVpreF) vaccine for ...

With the arrival of new vaccines for respiratory syncytial virus (RSV), Canadian seniors are faced with a critical decision: Is it worth getting the shot, especially if it’s not covered by public ...

Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use may ...

Please provide your email address to receive an email when new articles are posted on . “What surprised us most was the magnitude and consistency of the difference we observed in real-world conditions ...

Please provide your email address to receive an email when new articles are posted on . In 2023, the FDA approved two new powerful tools to protect infants against RSV: a maternal vaccine and a ...

Respiratory syncytial virus (RSV) infections in older adults lead to significantly more severe health outcomes and long-term cardiovascular complications compared to other common causes of ...

Viral and bacterial infections' overlapping symptoms and signs can complicate RSV diagnosis and lead to unnecessary antibiotic prescriptions. In this study, children who had RSV detected via a rapid ...

Adults hospitalized with an acute respiratory syncytial virus (RSV) infection faced an increased risk of cardiorespiratory events such as heart attack or stroke in the weeks afterward, according to a ...

Among adults with outpatient respiratory syncytial virus (RSV) infections across six RSV seasons, roughly one in 20 were hospitalized within 28 days, according to a large cohort study that used data ...